Treatment-Related Side Effects Associated with Physical Activity in Breast Cancer Survivors
the Cancer Therapy Advisor take:
Sedentary behavior (SED) was associated with increased levels of treatment-related side effects in breast cancer survivors (BCS), according to an article published online in the journal Psycho-Oncology.
In this study, 195 BCS completed questionnaires regarding demographics, medical variables, and treatment-related side effects, such as pain, fatigue, and depression symptoms.
Accelerometers were used to objectively measure levels of moderate-to-vigorous intensity physical activity (MVPA), light physical activity (PA), and SED.
Results showed that the interaction effect of MVPA by SED was significantly related to pain, fatigue, and depression (P=0.02, P=0.01, P=0.006, respectively).
Furthermore, BCS with lower levels of MVPA and higher levels of SED were more likely to have higher levels of pain, fatigue, and depression (P=0.06, P< 0.001, P=0.08, respectively).
Treatment-related side effects were more prevalent in BCS with higher levels of SED and lower levels of MVPA. However, SED was not significantly associated with fatigue, pain, or depression among survivors with high levels of MVPA.
The study suggests promoting health and physical activity messages as a means of improving management of treatment-related symptoms.
Sedentary behavior was associated with increased levels of treatment-related side effects in breast cancer survivors.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models